Terms: = Testicular cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
12 results:
1. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
3. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
[TBL] [Abstract] [Full Text] [Related]
4. Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies.
Giampietri C; Scatozza F; Crecca E; Vigiano Benedetti V; Natali PG; Facchiano A
J Transl Med; 2022 Oct; 20(1):467. PubMed ID: 36224560
[TBL] [Abstract] [Full Text] [Related]
5. Sperm Autoantigenic Protein 17 Predicts the prognosis and the Immunotherapy Response of cancers: A Pan-cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract] [Full Text] [Related]
6. Promising Immunotherapy in Metastatic testicular Sex Cord Stromal Tumours After First-Line Chemotherapy.
Shang B; Cao C; Jiang W; Shi H; Bi X; Cui C; Shou J; Zheng S; Zhang J; Zhou A; Li C; Ma J
Front Immunol; 2021; 12():720359. PubMed ID: 35082775
[TBL] [Abstract] [Full Text] [Related]
7. Immune mechanisms and possible immune therapy in testicular germ cell tumours.
Chovanec M; Mardiak J; Mego M
Andrology; 2019 Jul; 7(4):479-486. PubMed ID: 31169364
[TBL] [Abstract] [Full Text] [Related]
8. Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer.
Oing C; Bokemeyer C
Curr Opin Urol; 2018 Sep; 28(5):479-484. PubMed ID: 29957683
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
[TBL] [Abstract] [Full Text] [Related]
10. pd-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Nayak L; Iwamoto FM; LaCasce A; Mukundan S; Roemer MGM; Chapuy B; Armand P; Rodig SJ; Shipp MA
Blood; 2017 Jun; 129(23):3071-3073. PubMed ID: 28356247
[TBL] [Abstract] [Full Text] [Related]
11. Immunotherapy advances in uro-genital malignancies.
Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of programmed-death-1 receptor (pd-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract] [Full Text] [Related]
